Tele: 561.316.3330
Breaking Medical Device News

Tuesday, September 21, 2021


HomeAstrotech CorporationAstrotech’s 1st Detect Announces Successful Pre-Clinical Trials for Mass Spectrometer Used as a Rapid Bedside Breathalyzer

Astrotech’s 1st Detect Announces Successful Pre-Clinical Trials for Mass Spectrometer Used as a Rapid Bedside Breathalyzer

Astrotech (NASDAQ: ASTC) subsidiary 1st Detect, in collaboration with The University of Texas Health Science Center, now called UT Health San Antonio, announced today positive preliminary results in pre-clinical trials for the BreathDetect 1000 – a rapid bedside breathalyzer for detecting bacterial infections in the respiratory tract, such as hospital-acquired pneumonia (HAP).

Working with cystic fibrosis patients at a University Health System clinic in San Antonio, Dr. Edward G Brooks, MD and his team are targeting two of the most fatal bacterial strains found in HAP. Currently in the verification and validation phase after conducting successful bacterial culture headspace trials, the first human trials were initiated on May 22, 2017.

s“1st Detect’s BreathDetect 1000 has successfully identified several unique volatile organic compound (VOC) metabolites from Staphylococcus and Pseudomonas bacteria in human breath samples. The BreathDetect 1000 could significantly enhance the physician’s ability to treat patients correctly. By sampling directly from the lungs, the BreathDetect 1000 would speed up the current diagnosis process substantially – which, in turn, could reduce the misdiagnosis of diseases and subsequent antibiotic resistance; decrease the length of hospital stays; and most importantly, save lives, said Dr. Brook

With current diagnosis methods, physicians wait up to three days for the lab to identify the organism, and another two days to receive the antibiotic resistance profile. In the meantime, they prescribe broad spectrum antibiotics – leading to the urgent public health threat of antibiotic resistance and contributing to the re-emergence of deadly diseases such as methicillin-resistant Staphylococcus aureus (MRSA).

Thomas B. Pickens III, CEO of 1st Detect and parent company Astrotech added, “In this early stage of product validation, we’re extremely encouraged by the BreathDetect 1000’s high level of specificity and the progress UT Health San Antonio has made acquiring and validating human breath samples.   Additional human subject testing and development is underway.”

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

By using this website you agree to accept Medical Device News Magazine Privacy Policy